Skip to main content
Clinical Trials/NL-OMON39506
NL-OMON39506
Completed
Phase 4

An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings - B1831006

Pfizer0 sites1 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
factor VIII deficiency
Sponsor
Pfizer
Enrollment
1
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
November 2, 2016
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Pfizer

Eligibility Criteria

Inclusion Criteria

  • 1\) Male subjects \<6 years of age with severe hemophilia A (FVIII:C \<1%) based on clinical records, including newborns.;2\) No prior exposure to factor products or any blood products.

Exclusion Criteria

  • 1\) Presence of any bleeding disorder in addition to hemophilia A.;2\) Treatment with any investigational agent or device within the past 30 days.;3\) Any condition(s) that compromises the ability to collect study\-related observations, or that poses a contraindication to study participation (these conditions include, but are not limited to, inadequate medical history to assure study eligibility; and expectation of poor adherence to study requirements).

Outcomes

Primary Outcomes

Not specified

Similar Trials